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Because the prevalence of methicillin-resistant Staph-
ylococcus aureus (MRSA) differs among the 3 countries 
forming the Euregio Meuse-Rhin (EMR) region (Belgium, 
Germany, and the Netherlands), cross-border healthcare 
requires information about the spread of MRSA in the EMR. 
We investigated the emergence, dissemination, and diver-
sity of MRSA clones in the EMR by using several typing 
methods. MRSA associated with clonal complexes 5, 8, 
30, and 45 was disseminated throughout the EMR. Dutch 
isolates, mainly associated with sequence types (ST) ST5-
MRSA-II, ST5-MRSA-IV, ST8-MRSA-IV, and ST45-MSRA-
IV had a more diverse genetic background than the isolates 
from Belgium and Germany, associated with ST45-MRSA-
IV and ST5-MRSA-II, respectively. MRSA associated with 
pigs (ST398-MRSA-IV/V) was found in the Dutch area of 
the EMR. Five percent of the MRSA isolates harbored Pan-
ton-Valentine leukocidin and were classiﬁ  ed as community-
associated MRSA associated with ST1, 8, 30, 80, and 89. 
A
lmost one third of the European population lives in 
a border region (Euregio). These border regions have 
collaborated since the late 1950s, especially in the ﬁ  eld of 
healthcare (1). Cross-border patient mobility and free access 
to healthcare facilities within the European Union in gener-
al, and the Euregios in particular, are important for patients, 
medical doctors, healthcare facilities, and healthcare insur-
ance companies. The Euregio Meuse-Rhin (EMR), an area 
totaling 4,973 square miles (12,882 km2), is the border re-
gion of Belgium, Germany, and the Netherlands. The EMR 
comprises the Belgian provinces of Limburg and Liège, the 
German-speaking region of Belgium, the Aachen region in 
Germany, and the southern part of the Dutch province of 
Limburg. Each year, thousands of the 3.88 million inhab-
itants of the EMR cross the border to consult a medical 
specialist or a healthcare facility. Since 2003, hospitals in 
the EMR have built a strong collaboration. For example, 
the University Hospital Maastricht in the Netherlands and 
the University Hospital Aachen in Germany have an of-
ﬁ  cial agreement for the transfer of patients; consequently, 
dozens of patients are transferred each year between the 
2 hospitals. The same applies for the University Hospital 
Maastricht in the Netherlands and the General Hospital 
Vesalius in Belgium, between which nearly 100 patients 
are transferred each year. In an ofﬁ  cial publication of the 
European Commission (D. Byrne, Maastricht Conference 
on Cross-Border Health Care, Maastricht, the Netherlands, 
June 8, 2004), the EMR was mentioned as a model region 
for the European Union in the ﬁ  eld of cross-border health-
care and cross-border cooperation of hospitals. Further-
more, in July 2008, establishment of a pan-European uni-
versity hospital was announced, a collaboration among the 
university hospitals of Maastricht in the Netherlands and 
Aachen in Germany.
Of particular concern is cross-border dissemination of 
multidrug-resistant bacteria, such as methicillin-resistant 
Staphylococcus aureus (MRSA). The 3 countries forming 
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tal-isolated MRSA (23.6%, 13.8%, and 0.6% in Belgium, 
Germany, and the Netherlands, respectively) (2). Conse-
quently, cross-border transfer of patients may affect the 
dissemination and prevalence of MRSA, particularly when 
patients are transferred from countries with a relatively 
high prevalence to a country with a low prevalence.
A study of MRSA isolates from the EMR between De-
cember 1999 and February 2004 showed that isolates from 
clonal complex (CC) 5 and CC 8, which harbor the resis-
tance elements staphylococcal cassette chromosome mec 
(SCCmec) types I–IV, had been disseminated in the EMR 
(2). Our aim was to investigate the emergence, dissemina-
tion, and diversity of MRSA clones in the EMR during a 
10-month period in 2005 and 2006 and to compare the re-
sults with those of the previous study. We used sequencing 
of the short sequence repeat (SSR) region of the S. aureus 
protein A gene (spa typing), multilocus sequence typing 
(MLST), and SCCmec typing by PCR to investigate the ge-
netic background of all MRSA isolates. The spa locus was 
typed to provide more detailed information about prevalent 
MRSA clones in the EMR, especially because the previous 
study used only MLST analyses on a small subset of iso-
lates (2). Finally, because an increase of Panton-Valentine 
leukocidin (PVL)–positive MRSA isolates in the Nether-
lands has recently been observed (3), we investigated the 
possible spread of PVL-positive MRSA clones into hospi-
tals in the EMR, as well as the prevalence of the virulence 




We investigated 257 MRSA isolates, cultured during 
July 2005–April 2006 from 8 geographically closely related 
hospitals in the EMR. The hospitals included 1 hospital in 
Belgium (General Hospital Vesalius, Tongeren, 355 beds), 
2 hospitals in Germany (General Hospital Dūren, 521 beds, 
and Marien Hospital, Aachen, 321 beds), and 5 hospitals 
in the Netherlands (Atrium Medical Center, Heerlen, 811 
beds; Orbis Medical and Care Center, Sittard, 578 beds; 
Laurentius Hospital, Roermond, a 458-bed general hospi-
tal; University Hospital Maastricht, a tertiary hospital, 680 
beds; and VieCuri Medical Center, Venlo, a 554-bed gen-
eral hospital). The 257 MRSA isolates comprised 44 from 
Belgium, 92 from Germany, and 121 from the Netherlands. 
Isolates from the Belgian and German hospitals were from 
patients with MRSA infection; Dutch isolates were from 
patients carrying MRSA who were admitted to the Dutch 
hospitals. All isolates were identiﬁ  ed as S. aureus by Gram 
stain, catalase, and coagulase testing. The presence of the 
mecA gene was determined as described previously (2).
Antimicrobial Drug Susceptibility Testing
The susceptibility pattern of the MRSA isolates was 
determined according to the guidelines of the Clinical and 
Laboratory Standards Institute (4). Susceptibility to the fol-
lowing antimicrobial agents was determined as MIC: ce-
faclor, cefuroxime, clindamycin, ciproﬂ  oxacin, clarithro-
mycin, gentamicin, linezolid, moxiﬂ  oxacin,  oxacillin, 
penicillin, rifampin, teicoplanin, tetracycline, trimethop-
rim/sulfamethoxazole, and vancomycin. The susceptibility 
to fucidic acid and mupirocin (Rosco, Taastrup, Denmark) 
was determined by using the disk-diffusion method (5,6). 
MRSA isolates resistant to clarithromycin were tested for 
inducible clindamycin resistance by using the D-test (7).
Typing Methods
SCCmec typing was performed as described by Olivei-
ra et al. (8) with the modiﬁ  cation described previously (2). 
SCCmec type I elements that lack locus A (pls region) are 
indistinguishable (9) from SCCmec type IV elements when 
the method of Oliveira et al. is used (8). Furthermore, locus 
D (dcs region) is detected in both SCCmec types IV and 
VI (10). Therefore, SCCmec elements that were typed as 
SCCmec type IV using the method of Oliveira et al. (8) 
were further analyzed for presence of the ccrAB gene. 
SCCmec elements that could not be typed with the meth-
od of Oliveira et al (8) were further analyzed by using the 
methods of Ito et al. (11) and Zhang et al. (12).
Real-time ampliﬁ  cation of the spa gene was performed 
as described previously, followed by sequencing of the SSR 
region (13). The spa types were clustered into spa-CCs us-
ing the algorithm Based Upon Repeat Pattern (BURP) with 
the Ridom StaphType version 1.4 software package (www.
ridom.de). Because spa typing, together with the algorithm 
BURP, yields results concordant with typing results ob-
tained by MLST and pulsed-ﬁ  eld gel electrophoresis (13), 
the associated CCs, as determined with MLST, were allo-
cated through the Ridom SpaServer (http://spaserver.ridom.
de). To conﬁ  rm the association between MLST and spa 
typing, in combination with BURP, MLST was performed 
on a representative set of 12 strains of each major spa type 
and spa-CC (2).The presence of CNA, PVL, and TSST-1 
was determined with real-time PCR assays (14,15).
Results
Antimicrobial Drug Susceptibility Patterns
All 257 MRSA isolates were resistant to the β-lactam 
antimicrobial agents cefaclor, cefuroxime, oxacillin, and 
penicillin and were susceptible to linezolid, teicoplanin, 
and vancomycin. Most isolates were also resistant to cipro-
ﬂ  oxacin (84%) and moxiﬂ  oxacin (82%). The Dutch MRSA 
isolates were more often susceptible to ciproﬂ  oxacin and 
moxiﬂ  oxacin than were the Belgian and German isolates 
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(Table 1) (p<0.05). Furthermore, 78% of the MRSA isolates 
were resistant to clarithromycin, and 62%, to clindamycin. 
Susceptibility for clarithromycin and clindamycin differed 
by country (Table 1). A total of 41 MRSA isolates (19 from 
Belgium, 5 from Germany, and 17 from the Netherlands) 
was resistant to clarithromycin and susceptible to clindamy-
cin. The D-test showed that 31 (76%) of these 41 MRSA 
isolates had the inducible clindamycin resistant phenotype, 
including 15 from Belgium, 5 from Germany, and 11 from 
the Netherlands.
Distribution of MRSA Clones
SCCmec type IV was predominant in MRSA isolates 
from Belgium (77%), whereas MRSA isolates from Ger-
many harbored mainly SCCmec type II (82%). MRSA iso-
lates from the Dutch region harbored both SCCmec type II 
and IV (27% and 65%, respectively). Although 25 (10%) of 
the 257 MRSA isolates harbored an SCCmec element that 
could not be typed with the method of Oliveira et al. (8), 
they could be typed with the other methods. Seven MRSA 
isolates from Belgium harbored a SCCmec type III ele-
ment that lacked Tn554, which is usually characteristic for 
SCCmec type III. From the German region, 1 isolate that 
had a nontypeable SCCmec element harbored ccrC, locus 
E, and Tn554. The method of Zhang et al. (12) classiﬁ  ed 
this element as SCCmec type III. In the Netherlands, 17 
MRSA isolates contained a nontypeable SCCmec element 
as deﬁ  ned by Oliveira et al. (8). Ten of these were classi-
ﬁ  ed as SCCmec type IV, lacking locus D. The remaining 7 
harbored ccrC, characteristic for SCCmec type V, and were 
classiﬁ  ed as such with the method of Zhang et al. (12).
The 257 MRSA isolates were classiﬁ  ed into 36 dif-
ferent spa types, and BURP analysis showed 6 spa-CCs, 
4 singletons, and 3 spa types that were excluded from the 
analysis because the spa region was <5 spa repeats long 
(Table 2). MLST analyses showed 10 different STs among 
the 12 MRSA strains (Table 2). In the EMR, spa-CC 045 
(MLST CC5; 21%) and spa-CC 038 (MLST CC45; 75%) 
were found predominantly among MRSA isolates from the 
Belgian region; spa-CC 045 (MLST CC5; 85%) was found 
among isolates from the German region. The Dutch MRSA 
isolates were grouped into spa-CC 045 (MLST CC5; 39%), 
spa-CC 019/012/318/011/108 (MLST CC30 and CC398; 
15%), spa-CC 038 (MLST CC45; 15%), spa-CC with no 
founder 5 (MLST CC8; 16%), and spa-CC with no founder 
6 (MLST CC 45; 5%).
The ST5-MRSA-II (New York/Japan) clone was 
found mainly in Germany and the Netherlands, and the 
ST45-MRSA-IV (Berlin) clone was found in Belgium and 
the Netherlands. Furthermore, the ST5-MRSA-IV (Pediat-
ric) clone was found among the Dutch isolates. The MRSA 
isolates classiﬁ  ed as CC30 (ST30-MRSA-IV and ST36-
MRSA-II) were found only in the Netherlands. Most of the 
ST8-MRSA-IV (UK EMRSA-2/6) isolates were found in 
the Netherlands. Furthermore, several ST398-MRSA-IV 
and ST398-MRSA-V isolates were found in certain Dutch 
hospitals (Figure; Table 3).
Prevalence of Virulence Factors
Eleven (5%) of the 257 MRSA isolates were PVL-
positive. These isolates were associated with different ge-
netic backgrounds, i.e., ST1-MRSA-V (1 Dutch isolate), 
ST8-MRSA-IV, ST30-MRSA-IV (2 Dutch isolates each), 
ST45-MRSA-IV (1 isolate from Germany), ST80-MRSA-
IV (1 isolate from Germany and 2 from the Netherlands), 
ST89-MRSA-IV and ST89-MRSA-V (1 Dutch isolate 
each). Six of the PVL-positive isolates were positive for 
the cna gene, and none harbored the tst gene.
Nine (4%) of the 257 MRSA isolates were positive for 
the tst gene, 4 isolates were classiﬁ  ed as ST22-MRSA-IV, 
3 as ST36-MRSA-II, 1 as ST30-MRSA-IV, and 1 could 
not be classiﬁ  ed as an MRSA clone (spa type t779). All 
isolates were from the Netherlands and were positive for 
the cna gene; none harbored PVL.
Ninety-ﬁ  ve (37%) of the 257 MRSA isolates were 
positive for the cna gene (34 from Belgium, 9 from Ger-
many, and 52 from the Netherlands). All MRSA isolates 
from CC30, CC45, and ST398 harbored the cna gene. Fur-
thermore, 1 isolate from CC5, 1 from CC80, 6 classiﬁ  ed 
as singletons (associated with ST22 and ST89), and 2 ex-
cluded from the BURP analyses were positive for the cna 
gene.
Discussion
Because cross-border healthcare is an issue in the 
EMR, and the prevalence of MRSA differs among the 
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Table 1. Non–ȕ-lactam antimicrobial drug resistance patterns of 257 MRSA isolates in the Euregio Meuse-Rhin region, July 2005– 
April 2006* 
No. (%) resistant MRSA isolates 
Country 
No. 
isolates  CIP MXF CLI GEN CLR  SXT  TET  RIF  MUP  FUC 
Belgium  44  44 (100)  43 (98)  5 (11)  2 (5)  24 (55)  0  4 (9)  0  4 (9)  0 
Germany  92  89 (97)  89 (97)  78 (85)  5 (5)  83 (90)  0  3 (3)  2 (2)  1 (1)  1 (1) 
The Netherlands  121  84 (69)  79 (65)  76 (63)  11 (9)  93 (77)  3 (2)  22 (18)  0  8 (7)  1 (1) 
Total  257  217 (84)  211 (82)  159 (62)  18 (7)  200 (78)  3 (1)  29 (12)  2 (1)  13 (5)  2 (1) 
*MRSA, methicillin-resistant Staphylococcus aureus; CIP, ciprofloxacin; MXF, moxifloxacin; CLI, clindamycin; GEN, gentamicin; CLR, clarithromycin; SXT, 
trimethoprim/sulfamethoxazole; TET, tetracycline; RIF, rifampin; MUP, mupirocin; FUC, fucidic acid. No isolates showed resistance to linezolid, 
vancomycin, or teicoplanin. RESEARCH
countries forming the EMR, studying the possible emer-
gence, spread, and diversity of MRSA clones within and 
among these countries is important (2). In addition to 
MRSA clones from CC5 and CC8, found previously in the 
EMR, we observed MRSA isolates from CC30 and CC45. 
Furthermore, the Dutch isolates had a more heterogeneous 
genetic background than did MRSA isolates from Belgium 
and Germany. The prevalence of PVL-positive MRSA iso-
lates, belonging to ST1, 8, 30, 80 and 89, was higher than 
that found in the previous study (5% vs. 1.3%) (2).
The antimicrobial susceptibility of the MRSA isolates 
depends on the S. aureus lineage. The observation that the 
Dutch MRSA isolates were more often susceptible to cip-
roﬂ  oxacin and moxiﬂ  oxacin than were isolates from Bel-
gium and Germany can be explained by the fact that the 
isolates associated with ST5-MRSA-IV, ST22-MRSA-IV, 
and ST30-MRSA-IV, which were susceptible to ciproﬂ  oxa-
cin and moxiﬂ  oxacin, were mainly observed in the Nether-
lands. Although ST22-MRSA-IV is commonly susceptible 
to tetracycline, the ST22-MRSA-IV isolates in this study 
were resistant to tetracycline (16). S. aureus can harbor re-
sistance genes on mobile genetic elements on the genome, 
such as Tn554, as well as on plasmids, and these can be 
exchanged among S. aureus lineages, possibly because of 
antimicrobial drug pressure (17).
Primarily because of the Dutch “search-and-destroy” 
policy, isolates derived from colonized persons were avail-
able from the Netherlands, whereas isolates from Belgium 
and Germany were derived from infections. However, nasal 
carriers are at increased risk of acquiring MRSA infection 
(18). Consequently, not preventing the spread of MRSA 
among nasal carriers could lead to MRSA infection among 
these persons. Furthermore, the molecular epidemiology 
of MRSA can vary widely among hospitals. In the Dutch 
hospitals of the EMR, MRSA clones in each hospital were 
diverse, whereas in the Belgian hospital and 2 German 
hospitals, 1 MRSA clone predominated, showing that the 
number of hospitals is unlikely to have biased the results 
of our study.
Most of the MRSA isolates from Belgium were asso-
ciated with the Berlin clone (ST45-MRSA-IV). This clone 
has previously been found in Belgium, Germany, and the 
Netherlands (19). Most of the MRSA isolates from Germa-
ny were associated with the New York/Japan clone (ST5-
MRSA-II), previously found in Belgium and Germany 
(2,19). Most of the Dutch MRSA isolates belonged to 5 
MRSA clones (Table 3). Twenty-ﬁ  ve percent of the Dutch 
isolates were associated with the New York/Japan clone 
(ST5-MRSA-II), which has not been previously found in 
the Netherlands. The Pediatric clone (ST5-MRSA-IV), 
which represented 14% of the Dutch isolates, has been 
found in Belgium but not in the Netherlands (20,21). The 
Berlin clone (ST45-MRSA-IV), comprising 21% of the 
Dutch isolates, and the UK EMRSA-2/-6 clone (ST8-MR-
SA-IV), comprising 16% of the Dutch isolates, have been 
described in all 3 EMR countries (19,20). In addition, some 
less prevalent MRSA clones were observed. Four tst-posi-
tive MRSA isolates were associated with the UK EMRSA-
15 clone (ST22-MRSA-IV), previously found in Belgium 
and Germany but not in the Netherlands (19,20). Three 
Dutch MRSA isolates (spa type t012), harboring SCCmec 
type II, were associated with the CC30 lineage. These iso-
lates might be derived from the UK EMRSA-16 (ST36-
MRSA-II) clone (spa type t018) because spa types t012 and 
t018 differ in 1 spa repeat (r24) and are thus related. Fur-
thermore, both clones harbor the cna and tst genes (22,23). 
The highly endemic UK EMRSA-16 clone has not been 
observed before in the Netherlands, although this clone has 
previously been found in Belgium (24). Seven and 5 of the 
Dutch MRSA isolates were associated with ST398-MRSA-
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No. (%)  
spa types spa types ST CC
045 134 (52) 9 (25) t002, t003, t041, t045, t179, t447, t504, 
t838, t1107
ST5/ST225† CC5
019/012/318/011/108 19 (7) 7 (19) t011, t012, t019, t034, t108, t318, t582 ST36/ST398‡ CC30/CC398
038 58 (22) 5 (14) t038, t161, t740, t1288, t1310 ST45 CC45
044/042 4 (2) 4 (11) t042, t044, t131, t345 ST728/ST772§ CC1/CC80
No founder 5 22 (9) 2 (6) t008, t622 ST8 CC8
No founder 6 8 (3) 2 (6) t040, t553 ST45 CC45
Singletons 8 (3) 4 (11) t223, t375, t682, t786 ST217¶ CC22/CC89
Excluded# 4 (2) 3 (8) t457, t779, t1011
Total 257 (100) 36 (100)
*CC, clonal complex; MRSA, methicillin-resistant Staphylococcus aureus; ST, sequence type. Boldface indicates spa types on which multilocus 
sequence typing analysis was performed. 
†The strains spa typed as t003 and t045 had ST225, a single-locus variant of ST5 at the tpi locus. The strain spa typed as t447 had ST5. 
‡The strain spa typed as t011 had ST398, and the strain spa typed as t012 had ST36. 
§The strain spa typed as t044 had ST728, a single-locus variant of ST80 at the tpi locus. The strain spa typed as t345 had ST772, a single-locus variant 
of ST1 at the pta locus. 
¶The strain spa typed as t223 had ST217, a single-locus variant of ST22 at the tpi locus. 
#spa types with <5 spa repeat. Dissemination of MRSA, Euregio Meuse-Rhin Region
IV and ST398-MRSA-V, respectively, MRSA clones usu-
ally observed in pigs and among screening samples from 
pig farmers (25). The ST398 clone is now observed among 
screening samples of veterinarians from many countries in 
Europe, including Belgium and Germany (26). However, 
ST398 also has been isolated from several forms of human 
infections in Germany (27). The ST398 isolates from our 
study were positive for the cna gene, suggesting a higher 
virulence than that of the CNA-negative German ST398 
MRSA isolates (27). One Dutch MRSA strain was associ-
ated with the ST30-MRSA-IV clone, previously reported 
in Belgium, Germany, and France (20,21,28). The more 
diverse genetic background among MRSA isolates in the 
Dutch part of the EMR and the close cooperation of hospi-
tals in the EMR might suggest that importation of MRSA 
from Belgium and Germany has occurred through cross-
border healthcare (Table 4) (2). Other, less likely, explana-
tions for the diversity of MRSA clones in the Netherlands 
are the spread of MRSA from countries other than Belgium 
or Germany (19) and the emergence of new MRSA clones 
in vivo through transfer of the SCCmec element from 
methicillin-resistant coagulase-negative staphylococci to 
methicillin-sensitive S. aureus strains (29).
We could not determine the SCCmec type for 10% 
of the MRSA isolates by using the method of Oliveira et 
al. (8). This percentage was similar to that found in other 
studies (30,31) but higher than the 3% previously found 
in the EMR (2). The relatively large number of nontype-
able SCCmec types found in this study, probably formed 
by homologous recombination among SCCmec elements, 
supports the need for a new system for SCCmec typing and 
nomenclature (19).
The 7 Belgian MRSA isolates with the nontypeable 
SCCmec type III element were associated with CC5 and 
had the related spa types t045 and t1107 (http://spaserver.
ridom.de). Although SCCmec type III usually is found in 
the CC8 genetic background, such as in the ST239-MRSA-
III clone, an MRSA associated with CC5 (spa type t045) 
and harboring SCCmec type III recently was observed in 
Belgium (32). This might suggest that a new MRSA clone, 
ST5-MRSA-III, is beginning to emerge in Belgium.
The nontypeable SCCmec element of the German 
MRSA isolate harbored locus E and ccrC, speciﬁ  c for 
SCCmec type V (2), and Tn554, normally carried by 
SCCmec type II, III, and SCCmercury. Zhang et al. (12) 
classiﬁ  ed this element as SCCmec type III, but the SCCmec 
type III-speciﬁ  c primers used by this method are situated 
near locus E on SCCmercury (33), indicating that this ele-
ment could be a SCCmercury element containing mecA. 
Further investigation is needed into the structure of this 
element.
Previous studies have shown that MRSA isolates classi-
ﬁ  ed as community-associated usually harbor either SCCmec 












Figure. Distribution of the major methicillin-resistant Staphylococcus 
aureus (MRSA) clones in the Euregio Meuse-Rhin region, July 
2005–April 2006.
Table 3. Distribution of MRSA clones in the Euregio Meuse-Rhin 
region, by country, July 2005–April 2006* 
No. isolates 




ST5-MRSA-I 1 1 1 2
ST5-MRSA-II 1 75 30 106
ST5-MRSA-IV 2 17 19




ST45-MRSA-IV 33 8 25 66





NT MRSA  7† 1‡ 2§ 17
Excluded¶ 1 2 1 4
Total 44 92 121 257
*MRSA, methicillin-resistant Staphylococcus aureus; ST, sequence type; 
NT, nontypeable. Based on spa and staphylococcus cassette 
chromosome (SCC) mec typing.  
†These strains were classified into clonal complex (CC) 5 and had a 
nontypeable SCCmec type III element. 
‡This strain had a nontypeable SCCmec element belonging to CC30. 
§These strains harbored SCCmec type IV and could not be classified into 
a CC. 
¶spa types with <5 spa repeats. RESEARCH
type IV or V, and often PVL, but may differ in their genetic 
backgrounds (CC1, CC8, CC30, CC59 and CC80) (34). In 
the EMR, 5% of the MRSA isolates were positive for PVL, 
which is higher than the previously reported 1.3% (2). 
Thus, PVL-positive MRSA isolates with a heterogeneous 
genetic background are emerging in the EMR.
PVL-positive MRSA isolates associated with ST8-
MRSA-IV, ST30-MRSA-IV, and ST80-MRSA-IV have 
been isolated in the Netherlands (3,35). In the present 
study, 2 of the PVL-positive MRSA isolates harbored 
SCCmec type V. The different genetic background of 
these isolates, i.e., ST89 and ST772, a single-locus vari-
ant of ST1 at the pta locus, might suggest that SCCmec 
type V was introduced on different occasions into different 
S. aureus lineages. A PVL-positive ST772-MRSA-V has 
been observed in Germany (36). One of the PVL-positive 
isolates harbored SCCmec type I, and such isolates with a 
ST30 and ST37 genetic background have been described 
in the Netherlands (3). Although a recent study suggested 
that CNA and PVL combined contribute to virulence, only 
6 of the 11 PVL-positive MRSA isolates from the EMR 
harbored the cna gene (37). Further studies are needed to 
investigate the contribution of the combination of CNA and 
PVL to virulence.
The genetic background of 1 PVL-positive ST45-
MRSA-IV isolate from Belgium was similar to that of the 
Berlin clone. Hitherto, only PVL-negative isolates with this 
background have been found in EMR countries (19,20). 
PVL-positive MRSA isolates, associated with the major 
CA-MRSA clones (ST8-MRSA-IV, ST30-MRSA-IV, and 
ST80-MRSA-IV) have been reported from Belgium (38). 
Because PVL is situated on a phage, the genes encoding 
PVL might have been transferred to S. aureus with a CC45 
genetic background (34).
Our study found a PVL-positive MRSA isolate 
from Germany with spa type t042 (spa repeat pattern 
r26r23r12r34r34r33r34). This spa type is strongly re-
lated to spa types t044 and t131 (spa repeat patterns 
r07r23r12r34r34r33r34 and r07r23r12r34r33r34, respec-
tively), which are usually associated with the CA-MRSA 
ST80-MRSA-IV clone found in Germany (34).
The cna gene has been previously observed among 
MRSA isolates from CC22, CC30, and CC45 (23,29). 
Therefore, the presence of the can gene might, together 
with spa typing, be used as a marker for different genetic 
backgrounds.
MRSA clones associated with the hospital associated-
MRSA CCs 5, 8, 22, 30, and 45, the PVL-positive CA-
MRSA CCs 1, 8, 30, 80, and 89, as well as MRSA related 
to pigs (ST389-MRSA-IV/V) were observed in the EMR. 
Dissemination of these clones is possible because of the 
introduction of new MRSA clones associated with travel; 
with patients who have previously been admitted to a hospi-
tal abroad (cross-border healthcare); or with other high-risk 
patients, such as pig-farmers and their families. Therefore, 
a cross-border search-and-contain policy may help control 
the further spread of MRSA and reduce the ﬁ  nancial cost to 
hospitals, nursing homes, and the community in the EMR. 
The study was partly performed within the framework of 
the Interreg-III project “Cross-Border Health Care in the Euregio 
Meuse-Rhin.”
Dr Deurenberg is a postdoctoral fellow at the Department of 
Medical Microbiology at the University Hospital Maastricht. His 
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